logo.png
Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use
January 30, 2024 09:05 ET | Autonomix Medical, Inc.
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS,...
Logo.png
QHSLab Integrates Digital Medicine Assessments into Prominent Electronic Health Record (EHR) Company
January 30, 2024 08:30 ET | QHSLab, Inc.
This integration allows QHSLab access to more than 160,000 providers that are the exact match for target providers. WEST PALM BEACH, FL, Jan. 30, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the...
logo.png
Autonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ
January 29, 2024 08:05 ET | Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market THE WOODLANDS, TX., Jan. 29, 2024 (GLOBE NEWSWIRE)...
logo.png
Autonomix Medical, Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering
January 26, 2024 16:05 ET | Autonomix Medical, Inc.
Shares to begin trading on NASDAQ on January 29, 2024 under the ticker symbol “AMIX” THE WOODLANDS, TX., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the...
SeaStar_SM_LogoCard.png
SeaStar Medical Appoints David A. Green as Chief Financial Officer
January 11, 2024 16:05 ET | SeaStar Medical Holding Corporation
DENVER, Jan. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
logo.png
Autonomix Medical, Inc. to Present at the Startup Investing Webinar
January 11, 2024 09:00 ET | Autonomix Medical, Inc.
Live webcast roundtable discussion featuring Autonomix, Knightscope, and Infinity Fuel on Thursday, January 11th at 2:00 PM ET THE WOODLANDS, TX, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Autonomix...
SeaStar_SM_LogoCard.png
SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
January 09, 2024 08:30 ET | SeaStar Medical Holding Corporation
DENVER, Jan. 09, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
logo.png
Autonomix Medical, Inc. Provides Business Overview and Highlights Upcoming Milestones
January 04, 2024 10:00 ET | Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Patented two-fold technology that can potentially detect problematic neural signals and ablate nerves in one simple...
logo.png
GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR
January 02, 2024 12:33 ET | GlucoTrack, Inc.
Rutherford, NJ, Jan. 02, 2024 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device company focused on the design, development, and commercialization...
logo.png
GLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
November 30, 2023 17:39 ET | GlucoTrack, Inc.
Rutherford, NJ, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with...